Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in Hypertrophic Cardiomyopathy
NCT02948998Phase 4Unknown
- Sponsor
- Xinhua Hospital
- Start
- May 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of spironolactone in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Extent of Late Gadolinium Enhancement at 2 years. Status: unknown.
02
Drugs
spironolactone
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT02948998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948998.